NAT-Bendamustine: Discoloration
Last updated
Summary
Product
NAT-Bendamustine 100 mg/vial
Issue
Health products - Product quality
What to do
Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concerns.
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot number |
|---|---|---|---|---|---|
Natco Pharma |
Nat-Bendamustine |
DIN 02496895 |
Powder for Solution |
Bendamustine hydrochloride 100 mg/vial |
501902 |
Issue
The colour is out of specification in the affected lot(s).
What you should do
- Verify if your product is affected.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of Recall: Hospitals
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
Natco Pharma (Canada) Inc
2000 Argentia Road, Plaza 1, Suite 200,
Mississauga, ON, L5N 1P7
Published by
Health Canada
Audience
General public
Healthcare
Hospitals
Recall class
Type II
Identification number
RA-72343
Get notified
Receive notifications for new and updated recalls and alerts by category.